The Center for Biosimilars® provided news and insight during June 2021 in the form of interviews with key opinion leaders and coverage of major events. Catch up on what you missed.
The month of June 2021 saw many developments for biosimilars. The Center for Biosimilars® was on top of this news. Below is a selection of leading headlines that appeared during the month.
Amgen Senior Counsel on Interchangeables
The first interchangeable biosimilars are just around the corner, according to industry insiders, and these products are most likely to be insulins, for which there are currently no biosimilars. As Laura Sim, senior counsel at Amgen explained in a recent presentation, there are many unknowns with interchangeables. What happens if product lines evolve after biosimilars are granted interchangeable status? Will payers tend to give interchangeables higher formulary status than biosimilars?
It could turn out that interchangeables create more problems than they solve.
Cigna and the $500 Health Care Debit Card
Taking a page out of the COVID-19 vaccine book, Cigna is offering patients a cash award if they make the switch to money-saving biosimilars. Biosimilars advocates often wonder how deep the payer commitment is to biosimilars, and Cigna seems to be providing an answer with this debit card offer. The program rolls out in July 2021.
Can a Delayed Biosimilar Introduction Be a Good Thing?
Pay-for-delay settlements between originator companies and biosimilar developers have a bad reputation. It is assumed that both sides get something in the deal and patients and payers end up being the losers, because access to lower-cost medicines is denied. But Karin A. Hessler, assistant general counsel for the Association for Accessible Medicines, noted in a recent presentation that these settlements may avoid costly litigation that would otherwise delay biosimilar market entry for many more years—so, they actually help patients out.
Taking on the Patent Makers
Tahir Amin, Dip LP, formerly concocted patents for drug companies specifically to stretch out product exclusivities and keep competing products off the market. This line of work bothered his conscience and now, as co-executive director of I-MAK (The Initiative for Medicines Access and Knowledge), he’s a leading advocate for breaking down patent barriers to broader access to lifesaving medicines.
His interview on AbbVie, Humira, and patent thickets can be found here.
Deploying Biosimilars for Savings
The COVID-19 pandemic created a financial crisis for health care institutions, one that many are still trying to recover from. In an eloquent column, Sophia Z. Humphreys, PharmD, MHA, argues that if biosimilars have yet to fulfill their potential as money savers, now is their chance. Health care institutions have already demonstrated savings with these agents and these agents could help fix the COVID-19 financial imbalance, says Humphreys, director of System Pharmacy Clinical Services for Providence St. Joseph Health in Renton, Washington.
Tenderizing the Tender System in Europe
Biosimilar procurement in the European Union often depends on “tender” contests between drug producers, with the lowest-cost product often getting the contract. These procurement strategies may cause more harm than good, authors of a new survey contend. They argue for multi-winner bidding contests and a much broader range of criteria than cost for judging which biosimilars are chosen.
Alvotech’s Game Plan for Adalimumab
When it comes to biosimilar wars, there’s no shortage of action in the adalimumab arena. One of the contenders is Alvotech, of Reykjavik, Iceland, which hopes to score with a high concentration, citrate free formulation of this blockbuster medicine. Anil Okay, chief commercial officer for Alvotech, explains the company’s strategy in this video interview.
Copy Biologics in India
India is a case example of a developing nation that cannot yet produce biologics according to Western standards, although individual companies are standouts. The country has been ratcheting up its guidelines with the goal of meeting globally accepted quality criteria, and in this 2-part interview, a trio of panelists discuss these efforts and the potential for change.
Supreme Court and the Individual Mandate
A lot of work went into creating the biosimilars approval pathway, which is embodied in the Biologics Price Competition and Innovation Act (BPCIA) portion of the Affordable Care Act (ACA). So, it was a relief to biosimilars advocates in June when the nation’s highest court rejected a petition to strike down the whole of the ACA, including the BPCIA.
The court accomplished this rejection with subtlety of a tai chi master, using the minimum amount of legal leverage. In essence, it simply told plaintiffs they were not qualified to bring their suit. The court, as legal experts pointed out, never had to “address the merits” of the case.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.